Can you take Busulfan with Treosulfan?

Busulfan has a major potential interaction with Bleeding Disorder.

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

Busulfan has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

Busulfan has a major potential interaction with Fever.

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

Busulfan has a moderate potential interaction with Head Injury.

Seizures have been reported in patients receiving high doses of busulfan. Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.

Busulfan has a major potential interaction with Infection.

Busulfan can induce severe and prolonged myelosuppression. Treatment with busulfan should not be initiated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with busulfan. Close clinical monitoring of hematopoietic function is recommended.

Treosulfan has a moderate potential interaction with Liver Disease.

Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.

Treosulfan has a moderate potential interaction with Renal Dysfunction.

Treosulfan has not been studied in patients with moderate or severe liver and renal dysfunction.

Busulfan has a moderate potential interaction with Seizures.

Seizures have been reported in patients receiving high doses of busulfan. Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.

Treosulfan has a moderate potential interaction with Seizures.

There have been reports of seizures in patients following treatment with treosulfan. Patients should be monitored for signs of neurological adverse reactions, and clonazepam prophylaxis may be considered for patients at higher risk for seizures, including infants.

Busulfan has a moderate potential interaction with Thalassemia.

Cardiac tamponade during high dose busulfan therapy combined with cyclophosphamide has been reported in pediatric patients with thalassemia. Abdominal pain and vomiting may precede the tamponade. Cardiac tamponade can result in death and therapy with busulfan should be administered cautiously to patients with thalassemia.